Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
Abbott Labs (NYSE: ABT) made headlines in late March when the FDA gave emergency use authorization (EUA) for the company's COVID-19 test that runs on its ID NOW platform. Abbott also announced interim results last week from a clinical study in urgent care clinics that showed high levels of sensitivity for positive results and specificity for negative results.
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
Merck unveiled a barrage of Covid-19 programs Tuesday morning: Two experimental vaccines and one experimental treatment.
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (PFE) has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020. The private placement is contingent upon the closing of ContraFect’s public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.
AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?
The multiyear agreement provides for the supply of Valor Glass vials to a portion of currently marketed Pfizer drug products, pending regulatory approval. Since first launching its collaboration with Corning, Pfizer has continued to evaluate Valor Glass’ performance across several aseptic sites, utilizing multiple vial sizes, with a broad range of drug products from Pfizer’s sterile injectables portfolio. During this time, Valor Glass was accepted into and provisionally evaluated under the Food and Drug Administration’s (FDA) Emerging Technology Program.
Novavax has begun human trials, and Merck has joined the race with the acquisition of Themis and collaboration with non-profit IAVI.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162.5 million principal amount of Pfizer’s outstanding 7.200% notes due 2039 (the "Pfizer Notes") and up to $130.0 million principal amount of Wyeth’s 5.950% notes due 2037 (the "Wyeth Notes" and together with the Pfizer Notes, the "Notes"). Wyeth is a wholly-owned subsidiary of Pfizer. Pfizer and Wyeth do not endorse Offeror’s unsolicited tender offer, and neither Pfizer nor Wyeth is affiliated or associated with the Offeror, the tender offer or the offer documentation. The Offeror did not inform Pfizer of the tender offer, and Pfizer only became aware of the offer through a third party source. Further, there is no disclosure of information regarding the Offeror or any indication as to a source of financing for the offer in the offer documentation.
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Singapore's exports of pharmaceutical products have surged this year as the coronavirus pandemic prompts worldwide stockpiling of drug ingredients, providing a much needed salve for an economy facing its deepest recession in its 55-year history. Pharmaceutical output in Singapore has spiked 86% so far this year, official data showed on Tuesday, while export data for April showed pharmaceutical shipments surged 174% from the same month a year earlier, albeit from a low base. Singapore is one of the few countries in the world that exports more pharmaceuticals than it imports, according to Fitch Solutions.
In this article we will check out the progression of hedge fund sentiment towards Pfizer Inc. (NYSE:PFE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
One thing to start: Bill Ackman has sold his stake in Berkshire Hathaway, he disclosed on Wednesday, saying his hedge fund can seize on opportunities in the market faster than Warren Buffett’s sprawling conglomerate. If Ian Read had his way, AstraZeneca would be a unit of US pharma group Pfizer right now. Luckily for Pascal Soriot, the Frenchman, pictured below, who has run UK-based AstraZeneca since 2012, that didn’t come to pass.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
The coronavirus is taking a toll on mental health. The number of prescriptions for antidepressant, anti-anxiety and anti-insomnia medications filled per week increased 21% between Feb. 16 and March 15, 2020, according to a recent report by Express Scripts, a Cigna-owned (CI) pharmacy benefit manager. The study analyzed prescription claims filled between Jan. 19 and March 15 of this year among a sample of more than 31.5 million commercially-insured individuals, and found that claims peaked during the week ending March 15, when the novel coronavirus that causes COVID-19 was declared a pandemic.